GSK923295 as a potential antihepatocellular carcinoma agent causing delay on liver regeneration after partial hepatectomy

BACKGROUND: The clinical trials emerged centromere protein E inhibitor GSK923295 as a promising anticancer drug, but its function in hepatocellular carcinoma (HCC) remain needs to be fully elucidated, especially as chemotherapy after hepatectomy for liver tumors. We aimed to describe anti-HCC activi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Jia-Cheng, Wu, Ke, Zheng, Xing, Xu, Ming, Dai, Yi, Wei, Sai-Sai, Cai, Xiu-Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6595801/
https://www.ncbi.nlm.nih.gov/pubmed/30681497
http://dx.doi.org/10.1097/CM9.0000000000000053

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6595801/
https://www.ncbi.nlm.nih.gov/pubmed/30681497
http://dx.doi.org/10.1097/CM9.0000000000000053

Ejemplares similares